Department of Gastroenterology and Hepatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
J Gastroenterol. 2022 Nov;57(11):819-826. doi: 10.1007/s00535-022-01915-2. Epub 2022 Sep 1.
Pancreatic adenocarcinoma is a lethal cancer with poor response to chemotherapy and immune checkpoint inhibitors. Recent studies suggest that epigenetic alterations contribute to its aggressive biology and the tumor microenvironment which render it unresponsive to immune checkpoint blockade. Here, we review our current understandings of epigenetic dysregulation in pancreatic adenocarcinoma, its effect on the tumor immune microenvironment, and the potential for epigenetic therapy to be combined with immune checkpoint inhibitors.
胰腺导管腺癌是一种致命的癌症，对化疗和免疫检查点抑制剂的反应较差。最近的研究表明，表观遗传改变有助于其侵袭性生物学和肿瘤微环境，使其对免疫检查点阻断无反应。在这里，我们回顾了我们目前对胰腺导管腺癌表观遗传失调的理解，它对肿瘤免疫微环境的影响，以及表观遗传治疗与免疫检查点抑制剂联合应用的潜力。
